Compare TRIN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRIN | TRVI |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | 109 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2019 |
| Metric | TRIN | TRVI |
|---|---|---|
| Price | $16.80 | $14.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $16.00 | ★ $21.55 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.41 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $7.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.76 | $5.38 |
| 52 Week High | $17.38 | $16.12 |
| Indicator | TRIN | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 63.13 | 62.48 |
| Support Level | $14.31 | $10.07 |
| Resistance Level | $17.20 | $16.12 |
| Average True Range (ATR) | 0.34 | 0.76 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 67.57 | 78.12 |
Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.